Active substance |
nintedanib |
Holder |
Boehringer Ingelheim International GmbH |
Status |
Running |
Indication |
adult patients with non-IPF (idiopathic pulmonary fibrosis) chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype (PF-ILD's) |
Public documents |
|
Last update |
19/01/2021 |
Ofev
Last updated on 05/03/2021